A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC
R. Jeremy Nichols(Revolution Medicines (United States)), Chris J. Schulze(Revolution Medicines (United States)), Alun Bermingham(Revolution Medicines (United States)), Tiffany J. Choy(Revolution Medicines (United States)), Jim Cregg(Revolution Medicines (United States)), Gert Kiss(Revolution Medicines (United States)), Abby Marquez(Revolution Medicines (United States)), D. Reyes(Revolution Medicines (United States)), Mae Saldajeno-Concar(Revolution Medicines (United States)), Caroline E. Weller(Revolution Medicines (United States)), Daniel M. Whalen(Revolution Medicines (United States)), Yu Chi Yang(Revolution Medicines (United States)), Z. Wang(Revolution Medicines (United States)), Elena S. Koltun(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States)), Adrian L. Gill(Revolution Medicines (United States)), Richard L. Hansen(Revolution Medicines (United States)), S. M. Kelsey(Revolution Medicines (United States)), Mark A. Goldsmith(Revolution Medicines (United States)), Jacqueline A.M. Smith(Revolution Medicines (United States))
Cited by 23Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis